{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.9"},{"groupId":"OG001","value":"12.2"}]}],"title":"Serious Adverse Events: up to 19.3 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.2"},{"groupId":"OG001","value":"20.0"}]}],"title":"Serious Adverse Events: up to 49.7 Months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"180"}],"units":"Participants"}],"description":"A summary of serious adverse events is located in the Reported Adverse Event Module.","groups":[{"description":"pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care","id":"OG000","title":"Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed"},{"description":"pemetrexed + cisplatin followed by placebo plus best supportive care","id":"OG001","title":"Pemetrexed Plus Cisplatin Followed by Placebo"}],"paramType":"NUMBER","populationDescription":"Randomized population with all serious adverse events included.","reportingStatus":"POSTED","timeFrame":"Baseline randomization through 30-day post-discontinuation visit (up to 49.7 months)","title":"Percentage of Participants With Serious Adverse Events During Maintenance Phase","type":"SECONDARY","unitOfMeasure":"percentage of participants"}